<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834260</url>
  </required_header>
  <id_info>
    <org_study_id>1608042</org_study_id>
    <secondary_id>2016-001168-12</secondary_id>
    <nct_id>NCT02834260</nct_id>
  </id_info>
  <brief_title>Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study</brief_title>
  <acronym>IDEXACOR</acronym>
  <official_title>Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone: Tolerance and Safety Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune rejection episodes after penetrating keratoplasty occur in 30% of patients and
      constitute one of the main factors reducing graft survival. They mainly occur during the
      first 18 months. Prevention usually relies on a topical treatment with dexamethasone or
      prednisolone for standard risk patients. Eye drops are instilled three times a day during at
      least 3 months then tapered.

      OZURDEX is an absorbable small implant that releases a total of 700 micrograms dexamethasone
      during several months. It is indicated for intravitreal injection to treat macular edema.

      The investigators hypothesized that this implant could be used after subconjunctival
      injection during corneal graft, to prevent immune rejection and avoid repeated eyedrop
      instillations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>one month post graft</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score of ocular discomfort</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 15, Month 1, Week 5, Week 6, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12</time_frame>
    <description>analogic visual scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 15, Month 1, Week 5, Week 6, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12</time_frame>
    <description>digital picture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rejection episodes</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 15, Month 1, Week 5, Week 6, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft thickness</measure>
    <time_frame>one month post graft</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient requiring dexamethasone eyedrops</measure>
    <time_frame>one month post graft</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Date of disappearance of the implant</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 15, Week 5, Week 6, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of hemorrhage</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 15, Month 1, Week 5, Week 6, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12</time_frame>
    <description>with tomography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Keratoconus</condition>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <condition>Congenital Hereditary Stromal Dystrophy of the Cornea</condition>
  <arm_group>
    <arm_group_label>ozurdex group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone implant OZURDEX</intervention_name>
    <arm_group_label>ozurdex group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Keratoconus

          -  Fuch's dystrophy

          -  Hereditary stromal dystrophy

          -  Age 18 years old and more

          -  Signed informed consent

          -  Affiliated to the French Social Security

        Exclusion Criteria:

          -  Hypersensitivity to Dexamethasone or the excipients (polylactic and glycolic acid)

          -  Active ocular or periocular infection

          -  Advanced glaucoma

          -  History of herpetic or zoster keratitis

          -  Retinal disease for which an intravitreal injection of Ozurdex is planed for the next
             3-4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Caroline TRONE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Caroline TRONE, MD</last_name>
    <phone>(0)4 77 12 70 12</phone>
    <phone_ext>+33</phone_ext>
    <email>m.caroline.trone@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE</last_name>
    <phone>(0)4 77 12 04 69</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <phone>(0)4 77 12 70 12</phone>
      <phone_ext>+33</phone_ext>
      <email>m.caroline.trone@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GAIN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire GUILLEMOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>RÃ©my JULLIENNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles THURET, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>absorbable implant</keyword>
  <keyword>subconjunctival</keyword>
  <keyword>immune rejection</keyword>
  <keyword>safety profile</keyword>
  <keyword>dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

